Advertisement Pharmaceutical Business review - Page 485 of 5276 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
June 11, 2026

EMA validates Bayer’s asundexian application for ischaemic stroke

The European Medicines Agency (EMA) has validated Bayer’s marketing authorisation application for asundexian, an oral Factor XIa inhibitor, to prevent ischaemic stroke.

The study compared asundexian 50mg plus antiplatelet therapy to placebo in post-ischaemic stroke or high-risk TIA patients. Credit: Jo Panuwat D / Shutterstock.com.